|
GSK, Theravance Submit Respiratory Drug Candidate for U.S., EU Approval
GlaxoSmithKline (GSK) and Theravance have submitted applications in the U.S. and European Union (EU) for a new chronic obstructive pulmonary disease (COPD) and asthma treatment.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives